These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29122813)

  • 21. Biologic Drugs, Biosimilars, and Barriers to Entry.
    Shepherd JM
    Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin access and affordability in the USA: anticipating the first interchangeable insulin product.
    Luo J; Kesselheim AS; Sarpatwari A
    Lancet Diabetes Endocrinol; 2020 May; 8(5):360-362. PubMed ID: 32203681
    [No Abstract]   [Full Text] [Related]  

  • 24. Limited distribution networks stifle competition in the generic and biosimilar drug industries.
    Karas L; Shermock KM; Proctor C; Socal M; Anderson GF
    Am J Manag Care; 2018 Apr; 24(4):e122-e127. PubMed ID: 29668215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to achieve fairer prices for generic and biosimilar medicines.
    Ferrario A; Dedet G; Humbert T; Vogler S; Suleman F; Pedersen HB
    BMJ; 2020 Jan; 368():l5444. PubMed ID: 31932323
    [No Abstract]   [Full Text] [Related]  

  • 27. Economic perspective of cancer treatment in India.
    Natarajan A; Mehra N; Rajkumar T
    Med Oncol; 2020 Oct; 37(11):101. PubMed ID: 33057841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Projecting expenditure on medicines in the UK NHS.
    O'Neill P; Mestre-Ferrandiz J; Puig-Peiro R; Sussex J
    Pharmacoeconomics; 2013 Oct; 31(10):933-57. PubMed ID: 24037786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association.
    Harrington RA; Califf RM; Balamurugan A; Brown N; Benjamin RM; Braund WE; Hipp J; Konig M; Sanchez E; Joynt Maddox KE
    Circulation; 2020 Mar; 141(10):e615-e644. PubMed ID: 32078375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Availability and affordability of biologic versus non-biologic anticancer medicines: a cross-sectional study in Punjab, Pakistan.
    Saqib A; Iftikhar S; Sarwar MR
    BMJ Open; 2018 Jun; 8(6):e019015. PubMed ID: 29903783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulary Coverage of Brand-Name Adalimumab and Biosimilars Across Medicare Part D Plans.
    Klebanoff MJ; Li P; Lin JK; Doshi JA
    JAMA; 2024 Jul; 332(1):74-76. PubMed ID: 38842823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association.
    Kazi DS; Elkind MSV; Deutsch A; Dowd WN; Heidenreich P; Khavjou O; Mark D; Mussolino ME; Ovbiagele B; Patel SS; Poudel R; Weittenhiller B; Powell-Wiley TM; Joynt Maddox KE;
    Circulation; 2024 Jul; 150(4):e89-e101. PubMed ID: 38832515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The crisis in access to essential medicines in India: key issues which call for action.
    Bhargava A; Kalantri SP
    Indian J Med Ethics; 2013; 10(2):86-95. PubMed ID: 23697486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active Surveillance of Follow-on Biologics: A Prescription for Uptake.
    Sarpatwari A; Gagne JJ; Levidow NL; Kesselheim AS
    Drug Saf; 2017 Feb; 40(2):105-108. PubMed ID: 27838823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory From the American Heart Association.
    McClellan M; Brown N; Califf RM; Warner JJ
    Circulation; 2019 Feb; 139(9):e44-e54. PubMed ID: 30674212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The American Heart Association 2030 Impact Goal: A Presidential Advisory From the American Heart Association.
    Angell SY; McConnell MV; Anderson CAM; Bibbins-Domingo K; Boyle DS; Capewell S; Ezzati M; de Ferranti S; Gaskin DJ; Goetzel RZ; Huffman MD; Jones M; Khan YM; Kim S; Kumanyika SK; McCray AT; Merritt RK; Milstein B; Mozaffarian D; Norris T; Roth GA; Sacco RL; Saucedo JF; Shay CM; Siedzik D; Saha S; Warner JJ
    Circulation; 2020 Mar; 141(9):e120-e138. PubMed ID: 31992057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Societal value of generic medicines beyond cost-saving through reduced prices.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):701-11. PubMed ID: 25695926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.